Visual field defect associated with vigabatrin: Observational cohort study

British Medical Journal

Volumn 319, Issue 7218, 1999, Pages 1165-1166

  Wilton, L V ^a   Stephens, M D B ^a   Mann, R D ^a  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VIGABATRIN;

ARTICLE; DRUG MONITORING; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; VISUAL FIELD DEFECT;

EID: 0033619490     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.319.7218.1165     Document Type: Article

References (4)

1. 1 Eke T, Talbol JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997;314:180-1.
2. 2 Mackenzie R, Klistorner A, Asytnptomatic as well as symptomatic defects occur with vigabatrin. BMJ 1998;316:233.
3. 3 Mann RD. Prescription-event monitoring recent progress and future horizons. Br J Clin Pharmacol 1998;46:195-201.
4. 4 Committee on Safety of Medicines, Medicines Control Agency. Vigabatrin (Sabril) and visual field defects. Current problems in pharmacongilance. 1998;24:1.